Literature DB >> 16619217

Visual inspection as a cervical cancer screening method in a primary health care setting in Africa.

Ghislain Sangwa-Lugoma1, Salaheddin Mahmud, Samih H Nasr, Jean Liaras, Patrick K Kayembe, Rahma R Tozin, Pierre Drouin, Attila Lorincz, Alex Ferenczy, Eduardo L Franco.   

Abstract

We evaluated the feasibility and performance of visual inspection with acetic acid (VIA) and Lugol's iodine (VILI) for cervical cancer screening in a primary health-care setting in Kinshasa, Congo. Women (1,528) aged > or =30 years were screened independently by nurses and physicians by VIA and VILI and Pap cytology. Biopsy samples were obtained from women with abnormal colposcopies and from 290 randomly chosen women with normal colposcopy. Cytological and histological examinations were performed in Lyon and Montreal, respectively. The prevalence of cervical intraepithelial neoplasia (CIN) of grades 1, 2 and 3 was 4.5, 1.3 and 4%, respectively. Using biopsy as the reference, the sensitivity, specificity and negative predictive value (NPV) for > or =CIN 2 for VIA-nurse were 55.5% (95% CI: 34.7-76.2), 64.6% (95% CI: 62.0-67.1) and 96.8% (95% CI: 93.5-98.7), respectively. The corresponding values for VILI-nurse were 44.0% (95% CI: 24.2-63.8), 74.6% (95% CI: 72.3-76.9) and 96.7% (95% CI: 93.7-98.6). The equivalent parameters for physicians were 71.1% (95% CI: 46.7-95.5), 71.3% (95% CI: 68.9-73.6) and 98.6% (95% CI: 96.0-99.7) for VIA and 68.3% (95% CI: 42.5-94.0), 76.2% (95% CI: 74.0-78.4) and 97.2% (95% CI: 95.3-98.5) for VILI. The sensitivity of cytology ranged between 31 and 72%, depending on the abnormality threshold used to define positivity, with a corresponding specificity range of 94-99% and a NPV range of 97-99%. Our results show that VIA and VILI performed by nurses and physicians are slightly more sensitive but less specific than Pap cytology across multiple combinations of test and lesion thresholds. Given their lower cost and easy deployment, visual inspection methods merit further assessment as cervical cancer screening methods for low-resource countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619217     DOI: 10.1002/ijc.21972

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Andriod Device-Based Cervical Cancer Screening for Resource-Poor Settings.

Authors:  Vidya Kudva; Keerthana Prasad; Shyamala Guruvare
Journal:  J Digit Imaging       Date:  2018-10       Impact factor: 4.056

2.  Cervical cancer screening opportunities for Guinea-Bissau.

Authors:  Ivo Julião; Joana Savva-Bordalo; Nuno Lunet
Journal:  Porto Biomed J       Date:  2017-04-18

3.  See-and-treat approaches to cervical cancer prevention for HIV-infected women.

Authors:  Carla J Chibwesha; Susan Cu-Uvin
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

4.  Hybrid Transfer Learning for Classification of Uterine Cervix Images for Cervical Cancer Screening.

Authors:  Vidya Kudva; Keerthana Prasad; Shyamala Guruvare
Journal:  J Digit Imaging       Date:  2020-06       Impact factor: 4.056

5.  Evaluation of the FTA carrier device for human papillomavirus testing in developing countries.

Authors:  Paula Gonzalez; Bernal Cortes; Wim Quint; Aimée R Kreimer; Carolina Porras; Ana Cecilia Rodríguez; Silvia Jimenez; Rolando Herrero; Linda Struijk; Allan Hildesheim; Willem Melchers
Journal:  J Clin Microbiol       Date:  2012-09-19       Impact factor: 5.948

6.  Use of mobile telemedicine for cervical cancer screening.

Authors:  Kelly E Quinley; Rachel H Gormley; Sarah J Ratcliffe; Ting Shih; Zsofia Szep; Ann Steiner; Doreen Ramogola-Masire; Carrie L Kovarik
Journal:  J Telemed Telecare       Date:  2011-05-06       Impact factor: 6.184

7.  A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo.

Authors:  S Hovland; M Arbyn; A K Lie; W Ryd; B Borge; E J Berle; H Skomedal; T M Kadima; L Kyembwa; E M Billay; D Mukwege; R B Chirimwami; T M Mvula; P J Snijders; C J L M Meijer; F Karlsen
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

8.  An evaluation by midwives and gynecologists of treatability of cervical lesions by cryotherapy among human papillomavirus-positive women.

Authors:  Julia C Gage; Ana Cecilia Rodriguez; Mark Schiffman; Sydney Adadevoh; Manuel J Alvarez Larraondo; Bandit Chumworathayi; Sandra Vargas Lejarza; Luis Villegas Araya; Francisco Garcia; Scott R Budihas; Rodney Long; Hormuzd A Katki; Rolando Herrero; Robert D Burk; Jose Jeronimo
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

9.  Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.

Authors:  Adhemar Longatto-Filho; Paulo Naud; Sophie Fm Derchain; Cecília Roteli-Martins; Sílvio Tatti; Luciano Serpa Hammes; Luis Otavio Sarian; Mojca Eržen; Margherita Branca; Jean Carlos de Matos; Renata Gontijo; Marina Y S Maeda; Temístocles Lima; Silvano Costa; Stina Syrjänen; Kari Syrjänen
Journal:  Virchows Arch       Date:  2012-05-05       Impact factor: 4.064

10.  Comparing Papanicolau smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy.

Authors:  Michael H Chung; Kevin P McKenzie; Hugo De Vuyst; Barbra A Richardson; Farzana Rana; Ritesh Pamnani; Julia W Njoroge; Evans Nyongesa-Malava; Samah R Sakr; Grace C John-Stewart; Nelly R Mugo
Journal:  AIDS       Date:  2013-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.